Sodium taurodeoxycholic acid

牛磺脱氧胆酸钠

Report date: 2026/04/13 20:02:18

Base Information

Drug NameSodium taurodeoxycholic acid
Drug Alias NameTauroursodeoxycholate sodium牛磺去氧胆酸钠Taurodeoxycholic acidsodium taurodeoxycholateNuGel +[10] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionG-protein coupled bile acid receptor 1 agonistsNACHT, LRR and PYD domains-containing protein 3 inhibitors
TargetsG-protein coupled bile acid receptor 1NACHT, LRR and PYD domains-containing protein 3
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)EczemaDermatitis, Atopic +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryMainland China
Original Approved Date2011/05/06
Country/TerritoryUnited StatesRomaniaSouth Korea +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShaperon
China Registration ClassN/A

Develop Information

Active CompaniesKukjeon Pharmaceutical Co LtdHudson Therapeutics IncBridgebio Pharma Inc +[6] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)EczemaDermatitis, Atopic +[7] 
Inactive IndicationsSepsis

Other Information

ATC CodeN/A
Related LinksN/A